-+ 0.00%
-+ 0.00%
-+ 0.00%

AlphaValue/Baader Europe Lifts Sandoz Price Target After Updated FY26 Guidance

MT Newswires·11/17/2026 07:59:30
Listen to the news
07:59 AM EST, 11/17/2026 (MT Newswires) -- AlphaValue/Baader Europe increased its price target for Sandoz Group (SDZ.SW) to 89.9 francs from 84.5 francs as it took into account the Swiss drugmaker's updated guidance for full-year 2026. "Besides incorporating the 2026 guidance upgrade, we have revisited our out-year assumptions, considering 1/ the unrelenting growth of Sandoz's biosimilars (expanding at an average c.21% CER between 2022 and 9M 26) and 2/ the firm being among the few players with a competitive advantage in development, production and commercialisation of biosimilars," analysts wrote in a Tuesday note. "Not only is the biosimilar market envisioned to gallop at a nearly 20% rate over 2025-35 (backed by the upcoming patent expirations of massive multi-blockbuster biologic drugs), but they are also higher margin products than traditional generics." The research firm's adjustments to its out-year projections include an EBITDA growth rate of 6%, up from the previous estimate of 5.5%. "That said, our recommendation remains REDUCE, as stratospheric gains (+>260%) since Sandoz's public listing in October 2023 suggest that most of the favourable aspects of its growth story have been baked in by the markets," analysts said.